SAR445877 + cetuximab

SAR445877 + cetuximab is a combination therapy undergoing clinical investigation for advanced solid tumors. SAR445877 is a bi-functional fusion protein comprised of an anti-PD-1 antibody linked to the cytokine IL-15, designed to simultaneously block the PD-1 immune checkpoint and stimulate T-cell proliferation and activation. Cetuximab is a monoclonal antibody targeting the Epidermal growth factor receptor (EGFR), inhibiting tumor cell proliferation. The combination aims to enhance anti-tumor immune responses by simultaneously targeting immune suppression (PD-1 pathway) and tumor growth signaling (EGFR pathway). SAR445877 has shown particular promise in preclinical models for increasing the CD8/CD4 T cell ratio and has been associated with antitumor efficacy in advanced cancers such as non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, and gastric cancer[1][3][4][5]. Clinical trials involve intravenous administration, with SAR445877 dosed every two weeks or weekly, alone or with other anticancer therapies like cetuximab[1][5].